Alan Ashworth

Targeting Tankyrase 1 as a therapeutic strategy for BRCA-associated cancer

A. Ashworth, M. Cerone, C. Lord, 2009, Oncogene.

Establishment and characterisation of a new breast cancer xenograft obtained from a woman carrying a germline BRCA2 mutation

A. Ashworth, A. Vincent-Salomon, D. Stoppa-Lyonnet, 2010, British Journal of Cancer.

Identification of novel determinants of resistance to lapatinib in ERBB2-amplified cancers

A. Ashworth, J. Reis-Filho, D. Cunningham, 2014, Oncogene.

FXY2/MID2, a gene related to the X-linked Opitz syndrome gene FXY/MID1, maps to Xq22 and encodes a FNIII domain-containing protein that associates with microtubules.

A. Ashworth, T. Cox, S. Swift, 1999, Genomics.

Exploiting the DNA repair defect in BRCA mutant cells in the design of new therapeutic strategies for cancer.

A. Ashworth, A. Tutt, S. Jackson, 2005, Cold Spring Harbor symposia on quantitative biology.

The proteasome is involved in determining differential utilization of double-strand break repair pathways

A. Ashworth, C. Lord, K. Gudmundsdottir, 2007, Oncogene.